The move follows roughly 12 months after the Mount Laurel, New Jersey-headquartered firm – which focuses on the provision of psychiatry, paediatrics, pain and neurology clinical trial services – acquired Utah, based Phase I trial facility Lifetree.
CRI said that the decision to rebrand will streamline its communication networks, allow it to establish unified standard operating procedures (SOPs) and processes for Phase I to IV clinical trial services across the organisation.
The move is not the only brand –focused move CRI has made this year. In March the CRO teamed up with policy and health science consultants Pinney Associates to provide a “comprehensive clinical, regulatory, and post-marketing services for central nervous system (CNS) drugs.”